Pneumonia Treatment Study Enrollment Has Finished
Researchers have completed the enrollment phase for a clinical study testing a new drug intended to treat severe pneumonia.
Updated on Sept. 28, 2026 in Asthma
Live Poll
Should the FDA fast-track the development of new treatments for serious respiratory conditions?
Vasomune Therapeutics has completed patient enrollment for a Phase 2a clinical study of the investigational drug Pegevongitide. This study aims to evaluate the treatment in patients hospitalized with pneumonia who require supplemental oxygen.
Why it matters
Pneumonia can compromise pulmonary blood vessels, often leading to fluid buildup and difficulty breathing. This trial explores a potential new way to stabilize the lungs when standard respiratory support is required.
The Phase 2a trial (NCT05123755) uses a randomized, double-blind, placebo-controlled design to assess multiple intravenous doses of Pegevongitide. The study, which remains in the data analysis phase, focuses on safety, tolerability, and exploratory efficacy in hospitalized patients.
The players
Vasomune Therapeutics
A biopharmaceutical company focused on developing vascular-targeted therapies to treat acute respiratory distress and other conditions.
United States Department of Defense
The federal agency that provided funding support for the AV001-004 clinical study under award number W81XWH-21-1-0834.
The details
Pegevongitide works by activating the Tie2 receptor on the lining of blood vessels. By reinforcing these endothelial barriers, the drug is designed to reduce fluid leakage into the lungs, which is a common complication of severe pneumonia that impairs oxygen exchange.
Timeline
September 28, 2026: Vasomune announced the completion of patient enrollment for study AV001-004.
Health Landscape
This development sits within a broader effort to improve outcomes for severe respiratory infections by targeting vascular health. It aligns with the FDA Fast Track designation granted to Pegevongitide for the treatment of acute respiratory distress syndrome.
This clinical trial is currently in the research phase and is not available for patient use or prescription. Those interested in clinical research opportunities for respiratory conditions should discuss the feasibility and appropriateness of trial participation with their primary care physician.
The takeaway
The successful completion of patient enrollment marks a milestone in evaluating whether activating the Tie2 receptor can help manage severe pneumonia. Patients and families can track ongoing clinical trials through official registries like ClinicalTrials.gov to monitor when new data becomes available.
Further reading
For more information on respiratory health and emerging treatments, visit the Asthma section.
More information
To review corporate details regarding the development program, visit the Vasomune company information portal.
Live Poll
Should the FDA fast-track the development of new treatments for serious respiratory conditions?
